KORU Medical Systems opened lower at $3.86, compared with its previous close of $3.89. In the last trading session, the stock traded between $3.76 and $4.07. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in KORU Medical Systems is now worth
$ 104.53
Giving a profit of
$ 4.53 (4.53%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 2 Analysts
Buy
50%
Hold
50%
Sell
0%
Markets Today
Today's Change
$-0.20 (-5.14%)
Day High
$4.07
Day Low
$3.76
Day Open
$3.86
Prev Close
$3.89
Volume
3,09,756
1W Return
12.84%
1M Return
24.45%
3M Return
7.08%
6M Return
-8.21%
1Y Return
-1.07%
Fundamentals
Market Cap ($ Mn)
160
PE Ratio
-
PB Ratio
8.27
PEG Ratio
-
ROE
-15.85%
ROCE
-14.82%
EPS (TTM)
$0.01
Investment Returns
1 Week
12.84%
1 Month
24.45%
3 Months
7.08%
6 Months
-8.21%
9 Months
-19.08%
Financials
Quarterly
All values in $ Mn
8.8
Dec 24
9.6
Mar 25
10.2
Jun 25
10.4
Sep 25
10.9
Dec 25
12.0
Jun 26
Updates
11Nov
Piper Sandler lowers Koru Medical Systems price target to $4.5
Piper Sandler lowered Koru Medical Systems' price target to $4.5 from $5. Analyst Jason Bednar reiterated a Neutral rating on the stock. The price target reduction represents a $0.50 decrease.
Yesterday
11Nov
Koru Medical Q3FY26 Results: Sales miss estimate at $10.4M, EPS beats
Adjusted EPS of $0.02 beat consensus estimate of $(0.02) by 200%. Quarterly sales of $10.402M missed analyst estimate of $11.327M by 8.17%. Revenue remained flat year-over-year compared to Q3FY25. Full-year FY26 sales guidance raised to $48.0M-$48.5M from $47.5M-$48.5M.
2 days ago
21Oct
KORU Medical Systems Q3FY26 Results: Earnings call set for November 10, 2026
KORU Medical Systems will report Q3 2026 financial results on November 10, 2026. Conference call scheduled for 4:30 pm ET on the same day. Webcast archive available for six months post-event.
23 days ago
6Aug
Koru Medical withdraws Phesgo 510(k) to target high-volume molecules
Koru Medical Systems withdraws its Phesgo 510(k) application in the U.S. to pursue alternative oncology molecules with higher infusion volumes. International growth is expected to moderate in late 2026 due to European market conversions, though long-term confidence remains intact.
3mo ago
23Jul
Kaskela Law investigates KORU Medical Systems on behalf of shareholders
Kaskela Law LLC has launched an investigation into KORU Medical Systems, Inc. regarding potential securities law violations and breaches of fiduciary duty. The firm is representing current shareholders and seeking to determine if corporate actions were improper. Shareholders are urged to contact Kaskela Law for details on their rights.
3mo ago
16Jul
KORU Medical Systems to report Q2 2026 results on August 5
KORU Medical Systems, Inc. will announce its second quarter 2026 financial results on August 5, 2026, followed by a conference call at 4:30 p.m. ET. The company specializes in subcutaneous infusion solutions, including the Freedom Syringe Infusion System.
